Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. (VRCA) is a clinical-stage leader in dermatology therapeutics, pioneering FDA-approved treatments for complex skin conditions. This page provides investors and healthcare professionals with essential updates on the company's advancements in medical dermatology.
Access real-time news about Verrica's clinical trials, regulatory milestones, and strategic partnerships. Our curated collection includes updates on YCANTH® (the first FDA-approved molluscum contagiosum therapy), pipeline developments like VP-315 for skin cancers, and critical business decisions affecting the dermatology sector.
Key coverage areas include FDA regulatory updates, clinical trial results, research collaborations, and market expansion strategies. All content is verified through primary sources to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Verrica's latest developments in drug-device combination therapies and their impact on dermatological care. For comprehensive analysis of VRCA's position in medical dermatology, visit regularly for unfiltered updates directly from corporate communications and verified industry reports.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced a significant restructuring of its commercial organization to reduce costs and expand access to YCANTH®, its treatment for molluscum contagiosum. The company plans to:
- Reduce sales territories from 80 to approximately 35
- Focus on territories with high molluscum prevalence, previous cantharidin users, and strong insurance coverage for YCANTH®
- Expand sales efforts to include pediatricians in addition to dermatologists
- Reduce headcount in certain support functions
These changes are expected to reduce the company's overall cost structure by approximately 50% while maintaining support for YCANTH® as the new standard of care for molluscum contagiosum. The restructuring will result in a one-time charge of approximately $1.0 million.
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The event is scheduled for September 9-11, 2024. Ted White, President and CEO of Verrica, will engage in a fireside chat on Monday, September 9, 2024, at 1:30 pm ET.
Interested parties can access a live webcast of the event through a provided link or via the Investors/Presentations & Events section of Verrica's website. A replay of the webcast will be available for 90 days following the event, offering extended access to those unable to attend live.
Verrica Pharmaceuticals (NASDAQ: VRCA) reported Q2 2024 financial results, highlighting $4.9M in YCANTH® revenue. The company expanded YCANTH's distribution through Cencora, Inc. and announced positive Phase 2 results for VP-315 in basal cell carcinoma treatment. Verrica is preparing for a global Phase 3 Common Warts trial, expected to start in 1H 2025. Key financial highlights include:
- Net product revenue: $4.9M
- Collaboration revenue: $0.3M
- Net loss: $17.2M ($0.37 per share)
- Cash and equivalents: $31.9M (as of June 30, 2024)
The company expects continued YCANTH prescription growth in H2 2024, driven by a permanent J-Code and expanded insurance coverage.
Verrica Pharmaceuticals announced positive preliminary results from Part 2 of its Phase 2 clinical trial for VP-315, an investigational oncolytic peptide-based immunotherapy for basal cell carcinoma (BCC). Key findings include:
- No treatment-related serious adverse events reported
- Overall 86% reduction in tumor size for all treated lesions
- 51% of lesions achieved complete histological clearance
- Patients with residual tumor achieved an average 71% reduction in tumor size
The company views VP-315 as a potential first-line therapy for BCC, with possible use in primary and neoadjuvant settings. Verrica plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to determine next steps for VP-315's development.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company, has announced a conference call and webcast scheduled for August 14, 2024, at 8:30 a.m. ET. The event will cover two main topics:
1. The company's financial results for the second quarter ended June 30, 2024.
2. An overview of preliminary topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma.
Interested parties can join via phone or webcast. The webcast will be archived on Verrica's website for 90 days after the event.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced a settlement with Dormer Laboratories, resulting in Dormer halting sales of cantharidin-containing products in the U.S. Verrica's FDA-approved YCANTH is now the sole commercially available cantharidin therapy for molluscum contagiosum, a skin disease. CEO Ted White emphasized the importance of FDA approval for patient safety and indicated increased market usage for YCANTH as a result. The settlement underscores Verrica's commitment to preventing the distribution of non-FDA approved cantharidin products in the U.S.
Verrica Pharmaceuticals (Nasdaq: VRCA), a company focused on developing dermatology therapeutics, announced that its President and CEO, Ted White, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City.
The event will take place on June 6, 2024, at 3:30 pm ET. A live webcast of the event will be available through the investors' section of the Verrica website, with a replay accessible for 90 days post-event.
Verrica Pharmaceuticals announced an amendment to its collaboration with Torii Pharmaceutical to jointly conduct a global pivotal Phase 3 clinical trial for YCANTH® in treating common warts, expected to start in the first half of 2025. The cost will be equally shared, with Torii funding Verrica's portion through future payment offsets. Verrica highlighted the significant commercial prospects for YCANTH, given the 22 million common wart patients in the U.S. alone and no FDA-approved treatments. Torii will also make an $8 million milestone payment to Verrica upon the first patient dosing in Japan. The trial's initiation depends on feedback from the FDA and Japan's PMDA.
Verrica Pharmaceuticals Inc. reported $3.2M revenue for YCANTH® in Q1 2024. Over 228M lives covered by commercial insurance. Phase 2 results for VP-315 expected in Q2 2024. Conference call scheduled. Key achievements include FDA status, J-Code, and distribution agreements. Financially, $3.2M in product revenue, $0.6M in collaboration revenue. Increased expenses in SG&A and R&D. Net loss of $20.3M.
Verrica Pharmaceuticals Inc. announced that its President and CEO will present at upcoming investor conferences hosted by RBC Capital Markets and HCW BioConnect. The webcasts can be accessed on the company's website for 90 days after the events.
FAQ
What is the current stock price of Verrica Pharmaceuticals (VRCA)?
What is the market cap of Verrica Pharmaceuticals (VRCA)?
